Renoprotective effect of combination therapy in hypertensive patients with renal diseases.

Renoprotective effect of combination therapy in hypertensive patients with renal diseases. - Renoprotective effect of combination therapy in hypertensive patients with renal diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002752

Enrollment

200

Registered

2009-11-12

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients with renal diseases

Interventions

Addition of carcium channel blocker to angiotensin II receptor blocker Addition of diuretics to angiotensin II receptor blocker Angiotensin II receptor blocker only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Proteinuria equal or grater than (+) at dipstick test Estimated glomerular filtration rate equal or grater than 30 ml/min/1.73m2 Systolic blood pressure equal or grater than 130 mmHg and/or diastolic blood pressure equal or grater than 80 mmHg, or under treatment with angiotensin II receptor blocker

Exclusion criteria

Exclusion criteria: Uncontrolled hypertension (systolic blood pressure >200 mmHg) No use of carcium channel blocker or diuretics within 1 month Pregnancy or its possibility Hypersensitivity to or contraindication of olmesartan

Design outcomes

Primary

Measure	Time frame
1. Urinary protein excretion 2. Renal function	—

Secondary

Measure	Time frame
1. Blood pressure at office, home and 24 hours	—

Countries

Japan

Contacts

Public ContactKengo Furuichi

Kanazawa University Hospital Division of Nephrology

kfuruichi@m-kanazawa.jp076-265-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026